Tukysa Approved for Unresectable, Metastatic HER2-Positive Breast Cancer
MONDAY, April 20, 2020 -- The U.S. Food and Drug Administration announced Friday the approval of Tukysa (tucatinib) in combination with trastuzumab and capecitabine for treatment of advanced unresectable or metastatic human epidermal growth factor... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 20, 2020 Category: General Medicine Source Type: news
FDA Approves Tukysa (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
BOTHELL, Wash.--(BUSINESS WIRE) April 17, 2020 -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) granted approval to Tukysa™ (tucatinib) tablets in combination with trastuzumab and capecitabine... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 17, 2020 Category: Drugs & Pharmacology Source Type: news
FDA Approves sNDA for Neratinib in Combination with Capecitabine for HER2+ Breast Cancer
The FDA approved a supplemental new drug application for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received at least 2 prior anti-HER2-based regimens in the metastatic setting. (Source: CancerNetwork)
Source: CancerNetwork - February 26, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Study finds less-aggressive chemotherapy after initial treatment for metastatic colorectal cancer to be more beneficial
PHOENIX -- A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenance chemotherapy after initial treatment is more beneficial for patients whose disease is under control, compared with more aggressive treatment. A maintenance strategy with a fluoropyrimidine chemotherapy, such as 5-FU or capecitabine, is preferred, though observation with no chemotherapy is [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - December 18, 2019 Category: Research Source Type: news
New Standard Likely for Some Metastatic HER2 Breast Cancer New Standard Likely for Some Metastatic HER2 Breast Cancer
The investigational oral therapy tucatinib, when added to standard trastuzumab and capecitabine, resulted in a"clinically meaningful" lower risk of disease progression or death compared with placeboMedscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
SABCS: Addition of Tucatinib Ups Survival in HER2 & #43; Metastatic Breast Cancer
WEDNESDAY, Dec. 11, 2019 -- Adding tucatinib to trastuzumab and capecitabine is associated with improved progression-free and overall survival among heavily pretreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 11, 2019 Category: Pharmaceuticals Source Type: news
Dana-Farber Study: New Drugs Show Rare Promise Against Advanced Breast Cancer
SAN ANTONIO (AP) — Doctors on Wednesday reported unusually good results from tests of two experimental drugs in women with an aggressive form of breast cancer that had spread widely and resisted many previous treatments.
One drug showed particular ability to reach tumors in the brain, which are notoriously tough to treat.
The other pairs a sort of homing device for cancer cells with a payload of chemotherapy that’s released when it reaches its target.
“It’s a guided missile. It’s able to bring the chemotherapy directly to the cancer cell,” said the study leader, Dr. Ian Krop of the Dana-Farb...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 11, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated CBSN Boston Breast Cancer Dana Farber Cancer Institute Source Type: news
Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients
(University of Texas M. D. Anderson Cancer Center) Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2019 Category: Cancer & Oncology Source Type: news
Standard Adjuvant Chemotherapy Compared to Capecitabine in Early Breast Cancer
Researchers followed up 10 years after the CALGB 49907 trial to see which treatment led to longer recurrence-free survival. (Source: CancerNetwork)
Source: CancerNetwork - August 27, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
capecitabine (Xeloda)
Title: capecitabine (Xeloda)Category: MedicationsCreated: 12/14/2000 12:00:00 AMLast Editorial Review: 8/6/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 6, 2019 Category: Cancer & Oncology Source Type: news
ASCO: Low - Dose Chemo Benefits Advanced Gastroesophageal Cancer
Elderly, frail receiving 60 percent of oxaliplatin/capecitabine dose have noninferior PFS, less toxicity (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 3, 2019 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Geriatrics, Conference News, Source Type: news
Digital Pill May Improve Adherence to Oral Cancer Drugs Digital Pill May Improve Adherence to Oral Cancer Drugs
Oral drugs combined with a sensor can alert clinicians and caregivers when medication has been taken; a pilot trial with a digital capecitabine is underway in colorectal cancer patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 6, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Proteus debuts digital cancer drug
Proteus Digital Health said today that the first cancer patients were treated using its digital oncology therapy, which combines oral chemotherapy with an ingestible sensor.
Patients with stage 3 and 4 colorectal cancer at the University of Minnesota Health and Fairview Health Services were treated with digital capecitabine. The Redwood City, Calif.-based company plans to use its sensor-drug combination to record and share data such as the time and dose of chemotherapy that a patient ingests.
Get the full story at our sister site, Drug Delivery Business News.
The post Proteus debuts digital cancer drug appeared first on M...
Source: Mass Device - January 17, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Featured mHealth (Mobile Health) Oncology Pharmaceuticals Proteus Digital Health Source Type: news
TNBC Study of Capecitabine Mostly Disappoints, With One Exception TNBC Study of Capecitabine Mostly Disappoints, With One Exception
A study of adjuvant capecitabine in triple-negative breast cancer was largely negative, but disease-free and overall survival were improved in a subset of patients with the nonbasal-like phenotype.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 6, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Xeloda Disappoints in Early Triple-Negative Breast Cancer
(MedPage Today) -- No improvement after standard chemo, though subset may derive some benefit (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 6, 2018 Category: Hematology Source Type: news
